DiaMedica Therapeutics
DMAC
40 hedge funds and large institutions have $23.3M invested in DiaMedica Therapeutics in 2024 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 4 closing their positions.
2,757% more call options, than puts
Call options by funds: $200K | Put options by funds: $7K
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
56% more capital invested
Capital invested by funds: $14.9M → $23.3M (+$8.39M)
25% more funds holding
Funds holding: 32 → 40 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.28% less ownership
Funds ownership: 13.34% → 13.05% (-0.28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$454K |
| 2 |
CLG
Cooperman Leon G
|
+$413K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$259K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$214K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$314K |
| 2 |
Jane Street
New York
|
-$44.5K |
| 3 |
SCA
Stonebridge Capital Advisors
St Paul,
Minnesota
|
-$9.23K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.69K |
| 5 |
NMM
Naples Money Management
Naples,
Florida
|
-$3.36K |
DMAC Hedge Fund Activity: Q3 2024 in Review
40 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q3 2024, worth a combined $23.3M — up 56% from $14.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new DMAC positions and 4 closed out — a net gain of 8 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was LPL Financial, adding an estimated $454K. The largest seller was Aristides Capital, exiting entirely with an estimated $314K sold.
- 40 institutional investors held DiaMedica Therapeutics (DMAC) as of Q3 2024, up from 32 in Q2 2024.
- Funds reported $23.3M of DiaMedica Therapeutics stock for Q3 2024, up 56% quarter-over-quarter.
- 12 funds opened new DiaMedica Therapeutics positions in Q3 2024 and 4 closed out, a net change of +8 holders.
- The largest DiaMedica Therapeutics buyer in Q3 2024 was LPL Financial, an estimated $454K added.
- The largest DiaMedica Therapeutics seller in Q3 2024 was Aristides Capital, an estimated $314K sold.
Based on aggregated 13F filings for Q3 2024.